Shellie Fravel, PharmD
LightNews LightNews
banner
shelliefravel.bsky.social
Shellie Fravel, PharmD
@shelliefravel.bsky.social
87 followers 94 following 36 posts
Pharmacist | Clinical Professor

✨Interest in Nephrology Medicine #NephJC #NephSky
Posts Replies Media Videos
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
November 20, 2025 at 12:34 AM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
In just 30 min we will start #NephJC chat on our @nejm.org trial tonight, we’ll explore IgAN treatment closer to pathophysiology ORIGIN with a simultaneous publication during #KidneyWk
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy | NEJM
IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% ...
doi.org
November 19, 2025 at 1:30 AM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙‍♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36
Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
www.nephjc.com
November 18, 2025 at 12:29 PM
Reposted by Shellie Fravel, PharmD
nephrosage.bsky.social
High measured GFR as a predictor of all-cause mortality and cardiovascular disease in a prospective non-diabetic population cohort
More info:https://academic.oup.com/ndt/article/40/11/2091/8122110
@ndt-era.bsky.social, @hjanders.bsky.social
High measured GFR as a predictor of all-cause mortality and cardiovascular disease in a prospective non-diabetic population cohort
ABSTRACTBackground. High glomerular filtration rate (GFR) is generally regarded as beneficial but has been associated with cardiovascular disease (CVD) and
academic.oup.com
November 13, 2025 at 5:30 PM
Reposted by Shellie Fravel, PharmD
hswapnil.medsky.social
Missing all the overwhelming amount of science coming out of #KidneyWk?

The #NephJC crew has got you covered

Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
Kidney Week in Houston: Day 2 — NephJC
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
www.nephjc.com
November 8, 2025 at 2:06 PM
Reposted by Shellie Fravel, PharmD
edgarvlermamd.bsky.social
Indications for mineralocorticoid receptor antagonists (MRAs) in the management of cardio-kidney risk
#KidneyWk #Nephpearls #NephSky #Cardiorenal

✅ Check out this resource from @theisn.org
@isnkidneycare.bsky.social

👉 www.theisn.org/initiatives/...
November 8, 2025 at 12:46 PM
Reposted by Shellie Fravel, PharmD
dialysisbloke.bsky.social
Very proud to have lead the Australian arm of PISCES. Huge thanks for Charmaine Lok for the collaboration.
nejm.org NEJM.org @nejm.org · 17d
In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo

@asnkidney.bsky.social | #KidneyWk
American Society of Nephrology Kidney Week 2025 Original Article | Nov. 7, 2025 | NEJM.org Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis Fig. 1A. A Serious Cardiovascular Events The NEJM identity sits at the bottom.
November 7, 2025 at 7:38 PM
Reposted by Shellie Fravel, PharmD
hswapnil.medsky.social
Got #KidneyWk FOMO like @nephroseeker.medsky.social ?

We got you covered with daily coverage of the simultaneous publications!

www.nephjc.com/news/kidneyw...
Kidney Week in Houston: Day 1 — NephJC
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
www.nephjc.com
November 7, 2025 at 5:58 PM
shelliefravel.bsky.social
Shellie Fravel, PharmD joining from Iowa City. No COI. Ready to learn lots tonight! #NephJC
October 29, 2025 at 1:03 AM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky

✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social

www.nephjc.com/news/igan-kd...
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
www.nephjc.com
October 28, 2025 at 2:06 AM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline

🎨 Nice visual summary by @roxnonna23.bsky.social

www.nephjc.com/news/2025/10...
KDIGO 2025 IgA guidelines - Visual Abstract — NephJC
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera
www.nephjc.com
October 27, 2025 at 5:27 PM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
Last #NephJC short on individual data meta-analysis showing that although we love flozins for their extensive benefits we actually don’t completely understand how they work #Nephsky

✍️Meta by @willkidney.bsky.social & co
📝 Write up by @nephroseeker.medsky.social

www.nephjc.com/news/2025/10...
Empagliflozin, the kidney, and what we still don’t understand — NephJC
NephJC short on an empagliflozin meta-analysis
www.nephjc.com
October 21, 2025 at 9:25 AM
Reposted by Shellie Fravel, PharmD
kidneystories.bsky.social
A Review of the Management of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease - goo.gl/alerts/LioZE5 #GoogleAlerts
A Review of the Management of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is a chronic hereditary disorder and a major cause of end-stage renal disease (ESRD). Urolithiasis is a frequent complication in ADPKD and may cont...
goo.gl
October 16, 2025 at 12:03 AM
Reposted by Shellie Fravel, PharmD
hswapnil.medsky.social
Here’s @kidneyboy.bsky.social take on that study

pbfluids.com/2009/02/jour...

#NephJC
Journal Club: low protein diet
Effect of a very low protein diet on outcome: long-term follow-up.This is the long-term follow-up of the B group from the original MDRD study.Enrollment criteria:Age: 18-70Abnormal Cr 1.2-7 women 1…
pbfluids.com
October 15, 2025 at 1:14 AM
shelliefravel.bsky.social
Shellie Fravel, PharmD joining from Iowa City. No COI…not a big fan of restricting or supplementing. Looking forward to a good discussion tonight! #NephJC
October 15, 2025 at 1:06 AM
Reposted by Shellie Fravel, PharmD
runningkidneys.bsky.social
🫘 In advanced #CKD, protein supplementation boosts 📈 serum albumin (+1.76 g/L) & BMI (+0.29 kg/m²) but ❌ does not significantly improve health-related quality of life (HRQOL).

🔎 17 RCTs | 5699 screened
⚠️ Bias, short duration, heterogeneity

#NephJC
October 14, 2025 at 10:34 AM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
Check out the Spanish VA. #NephSky
Como siempre muchas gracias @dramiliflores.bsky.social

www.nephjc.com/news/2025/10/12/suplementacion-con-protenas-en-la-erc-el-resumen-visual
Suplementación con proteínas en la ERC: El Resumen Visual — NephJC
¿La suplementación con proteínas mejora la calidad de vida en la ERC avanzada? Revisa este resumen visual creado por Marc Soco , que sintetiza una nueva revisión sistemática y metanálisis! ¡No olvi...
www.nephjc.com
October 13, 2025 at 1:19 PM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR?

www.nephjc.com/news/2025/10...
Protein supplementation in CKD: The Visual Abstract — NephJC
We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?
www.nephjc.com
October 13, 2025 at 1:14 PM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
🗓️Join us 10/14/25 as we discuss:
Are you team PRO protein 💪 or team RESTRICT protein 🥗
The strategies seem to shift somewhat as CKD progresses to ESRD. What's the evidence say 🤔?
🕰️9pm EST only on Bluesky. #NephSky #MedSky
www.nephjc.com/news/proteins-eskd
The Protein Pendulum in CKD: supplement or restrict? — NephJC
This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.
www.nephjc.com
October 13, 2025 at 1:11 PM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
T2g
In fact, many GNs have a high risk of recurrence and were excluded from this study.
Since the recurrence of IgAN was not unexpected, should those patients have been excluded from this protocol? #NephJC
October 1, 2025 at 1:36 AM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
T1e:
Tacrolimus was withdrawn completely at 1 year post-transplant, only if at ≥6 months donor mixed hematopoietic chimerism (≥5% donor WBCs in whole blood) was achieved.

🎨 Infographic by @nephromommy-akshu.bsky.social & @nephroseeker.medsky.social #NephJC
October 1, 2025 at 1:23 AM
shelliefravel.bsky.social
Shellie Fravel joining from Iowa City. No COI. Excited to get started tonight! #NephJC
October 1, 2025 at 1:07 AM
Reposted by Shellie Fravel, PharmD
nephjc.bsky.social
Chimerism might just be the 🔑 to immune tolerance and ending the need for immunosuppression 🚫💊after transplantation 🫘.
Join the discussion 9/30/25 at 9 pm EST on Bluesky #NephSky #MedSky #NephJC
www.nephjc.com/news/chimera-tolerance-njqe334
Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression? — NephJC
This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.
www.nephjc.com
September 29, 2025 at 1:56 AM
Reposted by Shellie Fravel, PharmD
kidneyboy.bsky.social
I did a blog post about Apple's new Hypertension Detection System

pbfluids.com/2025/09/appl...
September 27, 2025 at 9:48 AM
Reposted by Shellie Fravel, PharmD
hswapnil.medsky.social
It’s that time of the year!

www.nephjc.com/news/2025/9/...

#NephJC
NephJC 2025 Fall Pledge Drive — NephJC
Help keep NephJC a vital, original, and unbiased source of medical education.
www.nephjc.com
September 22, 2025 at 12:43 AM